- Ultrapure Alginates: Properties and Applications in the Biomedical Field
- Tuesday, May 09, 2023
- 4:00 PM Central European Summer Time
- 1 hour
Summary
Detailed description:
Alginate is a natural polysaccharide extracted from brown seaweed. Its non-animal sourcing, biocompatibility, and availability in ultrapure form make it ideal for biomedical applications. Alginate can be crosslinked with divalent ions to produce hydrogels with tunable mechanical properties. It is composed of 1,4 linked β-D-mannuronate (M) and α-L-guluronate (G) – monomers that control its gelling behavior
This presentation will first provide an overview of ultrapure alginates produced by IFF NovaMatrix®. It will highlight the unique molecular properties of alginates including options to functionalize and create various gel morphologies. We will discuss specific studies showcasing the potential uses of alginates and their hydrogels in key biomedical applications, specifically cell-based immunotherapy and 3D bioprinting.
Key takeaways:
- Alginates’ fundamental properties and tunable gelation behavior.
- Potential modifications to alginates and how functionalization expands their areas of use.
- Recent literature data showing use of alginates in cell-based immunotherapy and 3D bioprinting.
Speakers
Dr. Marizela Delic-Schlumbohm
Associate R&D Manager, IFF Pharma Solutions
Dr. Marizela Delic-Schlumbohm is Associate R&D Manager for IFF’s Pharma Biotechnology platform (heritage DuPont Pharma Solutions). She is part of the Polymer Synthesis & Modification team located in Bomlitz (Germany), where she leads two laboratories. Marizela additional responsibility is the global technical support for the NovaMatrix® platform. Her role is to closely connect biotech customers’ technology needs with IFF’s R&D and manufacturing capabilities, as well as promoting and incubating additional opportunities in this space. Marizela holds a Master of Science degree in chemistry from the University of Technology in Vienna (TU Wien), and a PhD in Biotechnology (University of Natural Resources and Life Sciences Vienna, BOKU Wien).
Dr. Joshua Katz
Senior R&D Manager, IFF Pharma Solutions
Joshua S. Katz is Senior R&D Manager with IFF Pharma Solutions. He received his S.B. in Chemistry with a minor in Biomedical Engineering from the Massachusetts Institute of Technology in 2006. At MIT, he worked under the guidance of Prof. Darrell Irvine. From MIT he moved to the Department of Bioengineering at the University of Pennsylvania, studying under of Professors Jason Burdick and Daniel Hammer, and earning his PhD in 2011. After completing his PhD, he joined the Formulation Science group at Dow Chemical, where he worked on projects focused on encapsulation and controlled delivery for a variety of industries including pharmaceuticals, coatings, agriculture, and industrial composites. As part of the DowDuPont merger and subsequent split, Josh joined the Pharma Solutions business, leading the Colloids and Biopharma R&D group within DuPont Nutrition and Biosciences. In early 2021, DuPont Nutrition and Biosciences merged with IFF, leading to his present position. His research today focuses on fundamentals and applications of biopharmaceutical production and formulation.
Josh has won several awards recognizing his research accomplishments including a Graduate Research Fellowship from the National Science Foundation (2006), Best Poster in Competition from the MIT Biomedical Engineering Society (2006), and a named finalist for the DSM Polymer Technology Award 2011 presented in partnership with the POLY division of the American Chemical Society. He holds 4 US patents, is an author of 7 patent applications, and has over 30 peer-reviewed publications.
Comments are closed.